Brawn Biotech Ratios

Brawn Biotech Ltd Ratios

The Brawn Biotech Ltd Ratios page provides a complete fundamental analysis of Brawn Biotech Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Brawn Biotech Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Brawn Biotech Ltd (NSE: , BSE: 530207) is currently trading at ₹20.10, with a market capitalization of ₹60.31M. As a major player in the Health technology sector and Pharmaceuticals: major industry, Brawn Biotech Ltd remains a key stock for fundamental analysis using Brawn Biotech Ltd Ratios.

Brawn Biotech Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Brawn Biotech Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Brawn Biotech Ltd Ratios.

Historically, the Brawn Biotech Ltd P/E ratio has shown strong fluctuations:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The decline in Brawn Biotech Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Brawn Biotech Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.45.

Historical P/B trend:

• 2024: 1.45
• 2023: 1.18
• 2022: 0.79
• 2021: 0.72

Brawn Biotech Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Brawn Biotech Ltd P/S ratio currently stands at 0.36, an important part of Brawn Biotech Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 0.36
• 2023: 0.37
• 2022: 0.22
• 2021: 0.60

A stable or declining Brawn Biotech Ltd P/S ratio indicates cautious market sentiment.

Brawn Biotech Ltd Price to Cash Flow Ratio (P/CF)

The Brawn Biotech Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 111.39.

Historical Brawn Biotech Ltd Price to Cash Flow Ratio:

• 2024: 111.39
• 2023: 0
• 2022: 16.03
• 2021: 41.53
• 2020: 0

The rising Brawn Biotech Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Brawn Biotech Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Brawn Biotech Ltd EV currently stands at ₹46.76M, representing the total company valuation including debt.

Historical EV trend:

• 2024: 46.76M
• 2023: 56.03M
• 2022: 45.27M
• 2021: 49.81M

Brawn Biotech Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Brawn Biotech Ltd EV/EBITDA ratio is currently 0, a key metric in Brawn Biotech Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Stable Brawn Biotech Ltd EV/EBITDA indicates balanced valuation.

Brawn Biotech Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Brawn Biotech Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Brawn Biotech Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Brawn Biotech Ltd ROE currently stands at -41.30%, showing profitability and capital efficiency.

Historical ROE:

• 2024: -41.30
• 2023: -21.93
• 2022: -12.83
• 2021: -20.53

Declining ROE indicates pressure on profitability.

Brawn Biotech Ltd Ratios Analysis Summary

The Brawn Biotech Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Brawn Biotech Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Brawn Biotech Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.